Product Information
RANOLAZINE ER 500 MG TABLET is a generic product labeled by Major Pharmaceuticals, priced at $0.1649 per EA under NDC 00904750604. Its NADAC has been published 76 times since Apr 23, 2025.
FDA first approved this application on Nov 30, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The Low Outlier badge above means this manufacturer's average price in the Ranolazine market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
500 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904750604
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RANOLAZINEApproval Type
Generic (ANDA)
FDA Application
ANDA209953FDA Approved
11/30/2020
TE Code
AB
On Market Since
1/17/2025
Pharmacological Classes
Price Statistics
The NADAC for RANOLAZINE ER 500 MG TABLET has been published 76 times since Apr 23, 2025, and over the history we have for it it has declined 20.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1649 per EA |
|---|---|
| All-time high | $0.2071 (Jun 11, 2025) |
| All-time low | $0.1581 (Jul 22, 2026) |
| 52-week high | $0.1691 |
| 52-week low | $0.1581 |
| Median price | $0.1655 |
| Average price | $0.1729 |
| Largest weekly change | -7.5% (Aug 20, 2025) |
| Weeks tracked | 76 |
| Tracking since | Apr 23, 2025 |
Generic Alternatives
The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ranolazine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-anginal class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RANOLAZINE ER 500 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RANOLAZINE ER 500 MG TABLET, manufactured by Major Pharmaceuticals, is $0.1649 per EA (NDC 00904750604), effective Sep 30, 2026.
How has the price of RANOLAZINE ER 500 MG TABLET changed over time?
Over the history we have for it, the NADAC for RANOLAZINE ER 500 MG TABLET has declined 20.1%. It has been tracked across 76 weekly CMS publications since Apr 23, 2025.
What are the highest and lowest recorded NADAC prices for RANOLAZINE ER 500 MG TABLET?
Since Apr 23, 2025, the NADAC for RANOLAZINE ER 500 MG TABLET has ranged from a low of $0.1581 (Jul 22, 2026) to a high of $0.2071 (Jun 11, 2025), with a median of $0.1655 per EA.
Are there cheaper alternatives to RANOLAZINE ER 500 MG TABLET?
Yes. 12 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RANOLAZINE ER 500 MG TABLET, is $0.1609 per EA — about 2% below RANOLAZINE ER 500 MG TABLET.
Who manufactures RANOLAZINE ER 500 MG TABLET?
RANOLAZINE ER 500 MG TABLET (NDC 00904750604) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.